Pharma channel feed – Endpoints News

Pharma channel feed

How does the first half of 2018 measure up against the last 7 years for biotech IPOs?

7 years ago

Three years later the FDA finally lifts its hold on Aptose drug, setting the stage for a return to PhIb

7 years ago

Biogen goes deep into biosimilars, slapping down $700M for a major stake in Samsung Bioepis

7 years ago

Sarcoma expert George Demetri grades the latest statement on Nanobiotix's late-stage drug NBTXR3

7 years ago

C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals

7 years ago

Array wrestles FDA OK for its MEK/BRAF melanoma combo, to hit the pharmacy as Mektovi and Braftovi

7 years ago

Roivant undergoes major restructuring, cutting and shifting its staff

7 years ago

CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar

7 years ago

Achaogen hits, then misses: FDA OKs Zemdri for cUTIs, but rejects second indication

7 years ago

A monster discovery deal between AbbVie and Google’s Calico gets a new lease on the lab, with $1B more to back aging research

7 years ago

FDA to release list of surrogate endpoints in oncology

7 years ago

FDA OKs first cannabinoid, gives green light to GW Pharma’s Epidiolex for rare seizures

7 years ago

A slimmer FDA: White House proposes 30% cut to headcount under reorganization

7 years ago

Bristol-Myers clears another hurdle in Merck lung cancer showdown — but big challenges remain

7 years ago

J&J opens up a new biotech incubator, polishing the Big Apple's ambitions to create a major hub

7 years ago

Ex-Puma exec sentenced to prison stretch on insider-trading conviction — 'greed' made me do it

7 years ago

Novo takes on gut-brain axis discovery with Kallyope, focusing on obesity and diabetes

7 years ago

Roche bags full control of Foundation Medicine in $2.4B follow-up buyout

7 years ago

Valeant nosedives on CRL for plaque psoriasis, raising concerns over touted $1B pipeline

7 years ago

Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK

7 years ago

Nightstar's drug for rare vision loss admitted to FDA's gene therapy speedway

7 years ago

GSK wins yet another reprieve for blockbuster Advair franchise as Mylan is hit (again) with a CRL

7 years ago

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

7 years ago

Blame the ozanimod fiasco on the Receptos team? Just wait a sec, says ex-CEO, who sold the company to Celgene for $7.2B

7 years ago

First page Previous page 298 299 300301302 303 304 Next page Last page